ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported a net loss of $3.2 million for Q4 2025, an improvement from a net loss of $4.2 million in the same period last year. For the full year, ENDRA reported a net loss of $7.0 million, down from $11.5 million in 2024, primarily due to a significant decrease in operating expenses, which fell to $5.8 million from $10.8 million in the previous year. The company also highlighted its ongoing evaluation of strategic alternatives aimed at maximizing shareholder value, which was initiated by its Board of Directors on March 25, 2026. ENDRA plans to continue executing its strategic and operational initiatives during this review process without a set timetable for completion. The company demonstrated strong clinical progress with its TAEUS Liver device, achieving positive results in feasibility studies that position it as a clinical tool for future pharmaceutical trials. ENDRA's cash position as of December 31, 2025, was approximately $762,000, supplemented by $2.0 million in its Digital Asset Treasury, reflecting its capital management strategy.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.